Survival outcomes and toxicity of intraoperative intraperitoneal chemotherapy in advanced epithelial ovarian cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
ObjectiveTo assess the effect of single-dose cisplatin intraperitoneally administered during cytoreductive surgery in advanced epithelial ovarian cancer. MethodsData from patients who underwent surgical management followed by intravenous (IV) chemotherapy for stage III epithelial ovarian cancer from 2003 to 2012 were retrospectively reviewed. Subjects were divided into intraperitoneal (IP) and no-intraperitoneal (NIP) groups according to the administration of IP cisplatin 100 mg during the staging surgery. Clinical results such as survival outcomes and chemotherapeutic toxicity were compared between the two groups. ResultsThirty-seven patients in the IP group and 26 in the NIP group were identified. There were no significant differences between the two groups in basic characteristics such as age, histology, and surgical procedures. After the surgery with or without IP chemotherapy, there was no difference in the rate of either hematologic or gastrointestinal toxicity or in the rate of incompletion of following IV chemotherapy. Tumor recurrence occurred in 67.6% (25 patients) of IP group and 57.7% (15 patients) of NIP group (P=0.423) during the mean follow-up period of 37 months. The 3-year disease free-survival rate was 39.9% in the IP group and 35.8% in the NIP group, and the relative risk of recurrence was 0.864 (95% confidence interval, 0.447–1.673; P=0.665) in the IP group as compared with the NIP group. ConclusionIP chemotherapy with single-dose cisplatin during cytoreductive surgery is safe and feasible with little chemotherapeutic toxicity in advanced epithelial ovarian cancer, but no distinct improvement in survival could be demonstrated in the present study.
Abstract
ObjectiveTo assess the effect of single-dose cisplatin intraperitoneally administered during cytoreductive surgery in advanced epithelial ovarian cancer. MethodsData from patients who underwent surgical management followed by intravenous (IV) chemotherapy for stage III epithelial ovarian cancer from 2003 to 2012 were retrospectively reviewed. Subjects were divided into intraperitoneal (IP) and no-intraperitoneal (NIP) groups according to the administration of IP cisplatin 100 mg during the staging surgery. Clinical results such as survival outcomes and chemotherapeutic toxicity were compared between the two groups. ResultsThirty-seven patients in the IP group and 26 in the NIP group were identified. There were no significant differences between the two groups in basic characteristics such as age, histology, and surgical procedures. After the surgery with or without IP chemotherapy, there was no difference in the rate of either hematologic or gastrointestinal toxicity or in the rate of incompletion of following IV chemotherapy. Tumor recurrence occurred in 67.6% (25 patients) of IP group and 57.7% (15 patients) of NIP group (P=0.423) during the mean follow-up period of 37 months. The 3-year disease free-survival rate was 39.9% in the IP group and 35.8% in the NIP group, and the relative risk of recurrence was 0.864 (95% confidence interval, 0.447–1.673; P=0.665) in the IP group as compared with the NIP group. ConclusionIP chemotherapy with single-dose cisplatin during cytoreductive surgery is safe and feasible with little chemotherapeutic toxicity in advanced epithelial ovarian cancer, but no distinct improvement in survival could be demonstrated in the present study.
참고문헌 (14)
- Siegel R, "Cancer statistics, 2013", CA Cancer J Clin, 63, pp.11~30 (2013)
- "Cancer incidence" (2012)[URL]
- Esselen KM, "Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy", Gynecol Oncol, 127, pp.51~54 (2012)
- Dedrick RL, "Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer", Cancer Treat Rep, 62, pp.1~11 (1978)
- Armstrong DK, "Intraperitoneal cisplatin and paclitaxel in ovarian cancer", N Engl J Med, 354, pp.34~43 (2006)
- Markman M, "Phase III trial of standarddose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group", J Clin Oncol, 19, pp.1001~1007 (2001)
- Alberts DS, "Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer", N Engl J Med, 335, pp.1950~1955 (1996)
- "NCI clinical announcement: intraperitoneal chemotherapy for ovarian cancer" (2006)[URL]
- Ramarajapalli ML, "Technique of intraperitoneal chemotherapy using veress needle in patients with ovarian cancer", Int J Gynecol Cancer, 21, pp.1388~1390 (2011)
- Jaaback K, "Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer", Cochrane Database Syst Rev, (1), pp.CD005340~ (2006)
- Walker JL, "Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study", Gynecol Oncol, 100, pp.27~32 (2006)
- Deraco M, "Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study", BJOG, 119, pp.800~809 (2012)
- Myung Joo Kim, "Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer", Journal of Gynecologic Oncology, 23(2), pp.91~97 (2012), 대한부인종양학회[DOI]
- Ryu KS, "Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer", Gynecol Oncol, 94, pp.325~332 (2004)